April 02, 2025 – AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
April 23, 2024 – AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease
LSX World Congress : Life Science Partnering & Investment
28-30 April 2025 – One of the European’s leading partnering, strategy, and investment event – London UK
Bio 2025 : International Convention
16-19 June 2025 – The largest event for biotechnology representing the full ecosystem of biotech – Boston USA
Co-founder of Advicenne in 2007 and Panntherapi in 2020, he is an expert in the clinical development of innovative products for pharmaceutical and biotech industry. He has conducted many clinical studies and has successfully conducted numerous drug development programs in the field of the central nervous system (CNS) and kidney diseases. In particular, he successfully conducted the proof-of-concept study of the « Blockbuster » duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. His long history of interactions with the U.S. FDA and European (EMA) regulatory agencies provides Averoa with a strategic regulatory vision that is essential to its development.
